Sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-stage small cell lung cancer: a phase II clinical trial.

Signal Transduct Target Ther · 2024 · PMC11402985 · PMID 39278918

Europe PMC DOI

hedged sentences

0.0550

closest p · 1.1× alpha

0.1100

boldest claim

The sentences

showed a trendp = 0.055so close (0.05 < p ≤ 0.1)

Notably, the presence of KMT2D mutations showed a trend towards a negative impact on survival, with an HR of 4.103 (95% CI: 0.968–17.382, p = 0.055).

also in 53,322 other papers

did not reach statistical significancep = 0.11not close (p > 0.1)

The difference between pretreatment and on-treatment bTMB, expressed as ΔbTMB, proved greater for patients who achieved PR than for those with stable or progressive disease (SD/PD), and while this did not reach statistical significance ( p = 0.11), a noticeable trend was evident (Supplementary Fig 1 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.